Eventide Asset Management INSP Position
Active5-Fund ConvergenceEventide Asset Management increased their position in Inspire Medical Systems, Inc. (INSP) in Q4 2025, holding $40.6M worth of shares across 440,205 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
INSP is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout in 320 days (Feb 28, 2027), making the timing of Eventide's position particularly relevant.
Short interest stands at 14.6% of float with 3.4 days to cover, indicating significant bearish positioning against Eventide's long thesis.
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Full company profile →Short Interest
14.6%
3.4 days to cover
Eventide Asset Management INSP Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 440,205 | +183,547 | $40.6M |
| Q3 2025 | Increased | 256,658 | +100,000 | $19.0M |
| Q2 2025 | Decreased | 156,658 | -149,643 | $20.3M |
| Q1 2025 | Increased | 306,301 | +181,211 | $48.8M |
| Q4 2024 | Held | 125,090 | — | $23.2M |
| Q3 2024 | Held | 125,090 | — | $26.4M |
| Q2 2024 | Held | 125,090 | — | $16.7M |
| Q1 2024 | Held | 125,090 | — | $26.9M |
| Q4 2023 | Held | 125,090 | — | $25.4M |
| Q3 2023 | Increased | 125,090 | +16,870 | $24.8M |
| Q2 2023 | Held | 108,220 | — | $35.1M |
| Q1 2023 | New | 108,220 | +108,220 | $25.3M |
Frequently Asked Questions
Does Eventide Asset Management own INSP?
Yes. As of Q4 2025, Eventide Asset Management holds 440,205 shares of Inspire Medical Systems, Inc. (INSP) valued at $40.6M. This data comes from their SEC 13F filing.
How many hedge funds own INSP?
5 specialist biotech hedge funds currently hold INSP, including Deerfield Management, Driehaus Capital, Rock Springs Capital and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy INSP?
Eventide Asset Management's position in INSP was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's INSP position increasing or decreasing?
Eventide Asset Management increased their INSP position in the most recent quarter, adding 183,547 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
INSPCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →